Clinical trials: Adverse Drug Interaction
Pediatric Disorder, Genetic Predisposition
Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy
This study looks at how a medicine called trihexyphenidyl works in children with dystonic cerebral palsy. The study aims to understand how trihexyphenidyl is broken down and used in the body of pediatric patients and whether this…
- Conditions
- Pediatric Disorder, Genetic Predisposition, Dystonia, Secondary, Dystonia
- Trial name
- TRIKE2 (NCT06554288)
- Testing
- Trihexyphenidyl
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Children's Mercy Hospital Kansas City
COVID, Drug Effect
Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Adults With Polypharmacy Using Data From Large Medicare and Commercially Insured Populations
This retrospective study aims to perform a medication risk stratification using drug claims data and to simulate the impact of the addition of various repurposed drugs on the Medication Risk Score (MRS) in a health insurance…
- Conditions
- COVID, Drug Effect, Drug Interaction, Adverse Drug Event
- Trial name
- NCT04378881
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Tabula Rasa HealthCare
Pharmacogenetic Testing
Medication Optimization Using Pharmacogenetic Testing and the G-DIG to Reduce Polypharmacy in a Mental Health Population
Use of polypharmacy has significantly increased over the past two decades, which has unproven clinical benefit and is associate with an increased the risk of adverse side effects.
- Trial name
- MedOPT (NCT03468309)
- Testing
- Genecept Assay and G-DIG decision tool
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
Drug Reaction, Drug Hypersensitivity
An Evaluation of Healthcare Providers' Adherence to Pharmacovigilance Practices in an African Community
Egypt's several regions-rural, mixed, and urban-were given pre-designed surveys pertaining to drug adverse events and the role of pharmacovigilance in detection and reporting.
- Conditions
- Drug Reaction, Drug Hypersensitivity, Drug Abuse, Drug Interaction
- Trial name
- NCT06428162
- Testing
- questionner
- Where
- Egypt
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Deraya University
DRUG REACTIONS
Clinical Trial to Evaluate the Influence of Genotype and DDIs of Aspirin on the PK/PD of Clopidogrel and PK of Digoxin
Clinical trial to evaluate the influence of multiple aspirin administration on PK and PD of co-administered drugs
- Trial name
- NCT01775839
- Testing
- Aspirin+Clopidogrel/Digoxin(oral), Aspirin+Clopidogrel/Digoxin(IV)
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Endobronchial Metastases, Bronchoesophageal Fistula
Clinical Application Value of Remazolam Combined With Sugammadex Sodium in Anesthesia for Endotracheal Surgery Under Bronchoscopy
This study is a prospective, randomized, controlled trial. In this study, 30 patients who underwent endotracheal tumor resection under rigid bronchoscope or stent placement for acquired tracheoesophageal fistula were selected as…
- Conditions
- Endobronchial Metastases, Bronchoesophageal Fistula, General Anesthetic Drug Adverse Reaction
- Trial name
- NCT05468671
- Testing
- Remimazolam, Propofol, Rocuronium
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Zhejiang Cancer Hospital
Metastatic Renal Cell Carcinoma
Impact of the PRISM-care Multidisciplinary Oncology Program on Secured Drug Intake of Patients With Kidney Cancer
The rise of oral targeted therapies favors outpatient care of cancer patients but exposes them to new risks compared to the injectable chemotherapy in the hospital: non-adherence to treatment, inappropriate management of side…
- Trial name
- PRISM care (NCT02849535)
- Testing
- PRISM care program
- Where
- 12 sites in France
- Volunteers
- 190 people
- Sponsor
- Hospices Civils de Lyon
Ciprofloxacin Adverse Reaction
Ciprofloxacin Utilization and Adverse Events Occurrence in Community Pharmacy Setting
Background: Ciprofloxacin is a fluoroquinolone that is commonly used to treat a variety of diseases. Ciprofloxacin resistance is rising, resulting in suboptimal patient care.
- Trial name
- NCT05916105
- Testing
- Ciprofloxacin Tablets
- Where
- Egypt
- Volunteers
- 151 people
- Sponsor
- Damanhour University
Epilepsy
Standardized Educational Plan for Epilepsy Patients With Comorbidities
Epilepsy requires long-term drug treatment and is frequently associated with other clinical conditions. Combinations of antiepileptic drugs and other compounds are fairly common and increase with age.
- Trial name
- EDU-COM (NCT01804322)
- Testing
- Standardized educational plan, usual care
- Where
- Italy
- Volunteers
- 187 people
- Sponsor
- San Gerardo Hospital
Latent Tuberculosis, Human Immunodeficiency Virus
Doravirine, Rifapentine and Isoniazid Interaction
Drug therapy for persons living with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) co-infected with latent tuberculosis infection (LTBI) is complex.
- Conditions
- Latent Tuberculosis, Human Immunodeficiency Virus, Rifamycins Causing Adverse Effects in Therapeutic Use, Drug Interaction Potentiation
- Trial name
- DORIIS (NCT03886701)
- Testing
- Doravirine (DOR), Rifapentine (RPT), Isoniazid (INH)
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Walter K. Kraft
Migraine
Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound.
- Trial name
- NCT04818515
- Testing
- Atogepant, Ubrogepant
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- AbbVie
Cannabidiol, Drug Induced Liver Injury
Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions
Cannabidiol (CBD) is available as a prescription drug product for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex.
- Conditions
- Cannabidiol, Drug Induced Liver Injury, Drug Interaction
- Trial name
- NCT06192589
- Testing
- Cannabidiol, Citalopram, Morphine
- Where
- United States
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- Food and Drug Administration (FDA)
COVID, Drug Effect
Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy
This retrospective study aims to perform a medication risk stratification using drug claims data and to simulate the impact of the addition of various repurposed drugs on the Medication Risk Score (MRS) in elderly people enrolled…
- Conditions
- COVID, Drug Effect, Drug Interaction, Adverse Drug Event
- Trial name
- NCT04339634
- Testing
- Simulation of Repurposed Drugs for COVID-19
- Where
- United States
- Volunteers
- 12,873 people
- Sponsor
- Tabula Rasa HealthCare
Adverse Drug Interactions
Sulforaphane as an Antagonist to Human PXR-mediated Drug-drug Interactions
Adverse drug-drug interactions (DDIs) are responsible for approximately 3% of all hospitalizations in the US, perhaps costing more than $1.3 billion per year.
- Trial name
- NCT00621309
- Testing
- Rifampicin, sulforaphane plus rifampicin, sulforaphane alone
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University of Washington
Internet-Based Intervention
Evaluation of the First Pathways Game on Parent-child Interactions and Development for Vulnerable Children
Children's brains develop quickly in the first three years of life and are particularly sensitive to their environment. Adverse experiences, such as exposure to abuse and neglect, can increase children's risk for behavioral…
- Trial name
- NCT04902404
- Testing
- First Pathways Game
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University of Calgary
Adverse Drug Events, Adverse Drug Reactions
YouScript IMPACT Registry
This multicenter observational study aims to investigate the benefits of providing pharmacogenetic testing with the YouScript Personalized Prescribing System which includes a clinical decision support tool and individualized…
- Conditions
- Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED
- Trial name
- IMPACT (NCT02191358)
- Where
- 7 sites in United States
- Volunteers
- 800 people
- Sponsor
- Genelex Corporation
Transitions of Care, Patient Portals
Interactive Digital Health Tools to Improve Patient Safety in Acute Care
Study 1: The goal of this study is to implement and evaluate an interactive patient-centered discharge toolkit (PDTK) to engage patients and care partners in discharge preparation and communication with providers after discharge.
- Conditions
- Transitions of Care, Patient Portals, General Medicine, Discharge Checklist
- Trial name
- NCT03116074
- Testing
- Interactive Digital Health Tools
- Where
- United States
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Neonatal Intensive Care Unit, Medication Errors
Drug-Related Problems in Neonatal Patients
Drug-related problems in newborn babies have been reported with a rate of 4-30%. It is estimated that the higher rates of these problems in hospitalized children under the age of two are related to the variety of drugs used and…
- Conditions
- Neonatal Intensive Care Unit, Medication Errors, Drug-Related Problems, Adverse Drug Event
- Trial name
- NCT04899960
- Testing
- Clinical Pharmacist Intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 512 people
- Sponsor
- Hacettepe University
Adverse Drug Events, Adverse Drug Reactions
Pharmacogenetic Testing Among Home Health Patients
Patients meeting eligibility criteria will be randomized into two groups, one receiving pharmacogenetic testing and the other not receiving pharmacogenetic testing.
- Conditions
- Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED
- Trial name
- NCT02378220
- Testing
- Pharmacogenetic testing
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Genelex Corporation